ImmunoPET Imaging to Assess Target Engagement: Experience From 89Zr-Anti-Her3 mAb (GSK2849330) in Patients With Solid Tumors

Journal of Nuclear Medicine - China
doi 10.2967/jnumed.118.214726
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society of Nuclear Medicine

Related search

First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-Her3 Monoclonal Antibody, in Patients With Metastatic or Advanced HER3-Positive Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

Quantitative ImmunoPET of Prostate Cancer Xenografts With 89Zr- And 124i-Labeled Anti-Psca A11 Minibody

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2014English

Imaging Metastatic Castration-Resistant Prostate Cancer Patients With 89Zr-Dfo-Mstp2109a Anti-Steap1 Antibody

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

Genomic Profiling for Patients With Solid Tumors: A Single-Institution Experience

Annals of Clinical Oncology
2019English

89Zr-huJ591 Immuno-Pet Imaging in Patients With Advanced Metastatic Prostate Cancer

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2014English

CXCR4-Directed Imaging in Solid Tumors

Frontiers in Oncology
Cancer ResearchOncology
2019English

Using High Content Imaging to Quantify Target Engagement in Adherent Cells

Journal of Visualized Experiments
ImmunologyMolecular BiologyBiochemistryMicrobiology Chemical EngineeringNeuroscienceGenetics
2018English

EZH2 as a Therapeutic Target in Solid Tumors

Cancer Cell & Microenvironment
2015English

Immuno-Pet Imaging of 89Zr Labeled Anti-Pd-L1 Domain Antibody

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy